Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $22.5 million.

  • Maravai Lifesciences Holdings' Receivables - Net fell 2171.39% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 2171.39%. This contributed to the annual value of $38.5 million for FY2024, which is 2945.7% down from last year.
  • Maravai Lifesciences Holdings' Receivables - Net amounted to $22.5 million in Q3 2025, which was down 2171.39% from $27.9 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' Receivables - Net's 5-year high stood at $138.6 million during Q4 2022, with a 5-year trough of $22.5 million in Q3 2025.
  • For the 5-year period, Maravai Lifesciences Holdings' Receivables - Net averaged around $68.7 million, with its median value being $54.6 million (2023).
  • Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 13033.44% in 2021, then crashed by 6060.93% in 2023.
  • Maravai Lifesciences Holdings' Receivables - Net (Quarter) stood at $117.5 million in 2021, then increased by 17.97% to $138.6 million in 2022, then crashed by 60.61% to $54.6 million in 2023, then decreased by 29.46% to $38.5 million in 2024, then crashed by 41.49% to $22.5 million in 2025.
  • Its Receivables - Net stands at $22.5 million for Q3 2025, versus $27.9 million for Q2 2025 and $28.5 million for Q1 2025.